434 related articles for article (PubMed ID: 23733403)
21. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
Schulz JB; Rainer M; Klünemann HH; Kurz A; Wolf S; Sternberg K; Tennigkeit F
J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
[TBL] [Abstract][Full Text] [Related]
22. Donepezil and memantine for moderate-to-severe Alzheimer's disease.
Howard R; McShane R; Lindesay J; Ritchie C; Baldwin A; Barber R; Burns A; Dening T; Findlay D; Holmes C; Hughes A; Jacoby R; Jones R; Jones R; McKeith I; Macharouthu A; O'Brien J; Passmore P; Sheehan B; Juszczak E; Katona C; Hills R; Knapp M; Ballard C; Brown R; Banerjee S; Onions C; Griffin M; Adams J; Gray R; Johnson T; Bentham P; Phillips P
N Engl J Med; 2012 Mar; 366(10):893-903. PubMed ID: 22397651
[TBL] [Abstract][Full Text] [Related]
23. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer's Disease: A Randomized, Double-Blind Trial.
Homma A; Atarashi H; Kubota N; Nakai K; Takase T
J Alzheimers Dis; 2016 Mar; 52(1):345-57. PubMed ID: 26967222
[TBL] [Abstract][Full Text] [Related]
25. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
[TBL] [Abstract][Full Text] [Related]
26. The value of cholinesterase inhibitors for improving neuropsychiatric and functional assessment scores in patients with Alzheimer disease: a systematic review and meta-analysis of on placebo-controlled RCTs.
Zhang Y; Sun Y; Hu X; Yao Y; Wang J
Int J Surg; 2024 Jun; 110(6):3937-3945. PubMed ID: 38573101
[TBL] [Abstract][Full Text] [Related]
27. Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease.
Plosker GL
Drugs; 2015 May; 75(8):887-97. PubMed ID: 25899711
[TBL] [Abstract][Full Text] [Related]
28. Memantine benefits functional abilities in moderate to severe Alzheimer's disease.
Winblad B; Gauthier S; Aström D; Stender K
J Nutr Health Aging; 2010 Nov; 14(9):770-4. PubMed ID: 21085908
[TBL] [Abstract][Full Text] [Related]
29. Memantine in Alzheimer's disease: experience in an Alzheimer's disease assessment unit.
Sinforiani E; Pasotti C; Chiapella L; Malinverni P; Zucchella C
Aging Clin Exp Res; 2012 Apr; 24(2):193-6. PubMed ID: 22842837
[TBL] [Abstract][Full Text] [Related]
30. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
31. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study.
Bakchine S; Loft H
J Alzheimers Dis; 2007 Jul; 11(4):471-9. PubMed ID: 17656827
[TBL] [Abstract][Full Text] [Related]
32. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan.
Nakamura Y; Kitamura S; Homma A; Shiosakai K; Matsui D
Expert Opin Pharmacother; 2014 May; 15(7):913-25. PubMed ID: 24673497
[TBL] [Abstract][Full Text] [Related]
34. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
35. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies.
Wilcock GK; Ballard CG; Cooper JA; Loft H
J Clin Psychiatry; 2008 Mar; 69(3):341-8. PubMed ID: 18294023
[TBL] [Abstract][Full Text] [Related]
36. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data.
Dysken MW; Guarino PD; Vertrees JE; Asthana S; Sano M; Llorente M; Pallaki M; Love S; Schellenberg GD; McCarten JR; Malphurs J; Prieto S; Chen P; Loreck DJ; Carney S; Trapp G; Bakshi RS; Mintzer JE; Heidebrink JL; Vidal-Cardona A; Arroyo LM; Cruz AR; Kowall NW; Chopra MP; Craft S; Thielke S; Turvey CL; Woodman C; Monnell KA; Gordon K; Tomaska J; Vatassery G
Alzheimers Dement; 2014 Jan; 10(1):36-44. PubMed ID: 23583234
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
38. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
[TBL] [Abstract][Full Text] [Related]
39. Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?
Doggrell S
Expert Opin Pharmacother; 2003 Oct; 4(10):1857-60. PubMed ID: 14521495
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Donepezil in Chinese Patients with Severe Alzheimer's Disease: A Randomized Controlled Trial.
Jia J; Wei C; Jia L; Tang Y; Liang J; Zhou A; Li F; Shi L; Doody RS
J Alzheimers Dis; 2017; 56(4):1495-1504. PubMed ID: 28157100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
